Presentations – BioArctic

BioArctic’s partner Eisai presented results of lecanemab Phase 3 confirmatory Clarity AD study for Early Alzheimer’s disease at CTAD conference

November 30, 2022

BioArctic's partner Eisai presented the results from the large global Phase 3 confirmatory Clarity AD clinical study of lecanemab at the 2022 Clinical Trials on Alzheimer’s ...

Interim Report July – September 2022

October 20, 2022

An additional Phase 3 study in Alzheimer’s disease

Redeye Neurology Seminar

October 12, 2022

Gunilla Osswald, CEO, presented BioArctic at Redeye Neurology Seminar in Stockholm

Pareto Securities’ 13th Annual Healthcare Conference

September 7, 2022

Gunilla Osswald, CEO, presented BioArctic at Pareto Securities' 13th Annual Healthcare Conference in Stockholm

Nordea Small and Midcap Days

August 24, 2022

Gunilla Osswald, CEO, presented BioArctic at the Nordea Small and Midcap Days held in Stockholm

Latest data on lecanemab presented at Alzheimer’s Association International Conference (AAIC)

August 5, 2022

BioArctic AB’s partner Eisai presented new data for lecanemab (BAN2401), an investigational anti-amyloid beta (Aβ) protofibril antibody for the treatment of mild cognitive impairment (MCI) due ...

Interim Report April – June 2022

July 12, 2022

FDA grants priority review for lecanemab marketing application

Handelsbanken Mid/Small Cap Seminar

June 9, 2022

Gunilla Osswald, CEO, presented BioArctic at the Handelsbanken Mid/Small Cap Seminar held in Stockholm

BioStock Life Science Spring Summit

June 8, 2022

VP Communications & IR, Oskar Bosson, presented BioArctic at the BioStock Life Science Spring Summit

ProHearings

June 2, 2022

VP Communications & IR, Oskar Bosson, presented BioArctic at a ProHearings event in Stockholm

Interim Report January – March 2022

April 28, 2022

Decision on marketing approval for lecanemab is approaching

Kempen Life Sciences Conference

April 20, 2022

Gunilla Osswald, CEO, presented BioArctic at the Kempen Life Sciences Conference in Amsterdam

BioArctic and Eisai presented latest data regarding lecanemab at the AD/PDTM 2022 conference

18 mars, 2022

BioArctic and its partner Eisai presented data on the drug candidate lecanemab (BAN2401) – an investigational anti-amyloid-beta (Aβ) protofibril antibody being developed for the treatment of ...

Carnegie Healthcare Seminar

March 15, 2022

Gunilla Osswald, CEO, presented BioArctic at the Carnegie Healthcare Seminar in Stockholm

BioCapital Europe

March 10, 2022

Gunilla Osswald, CEO, presented BioArctic at the BioCapital Europe Conference in Amsterdam

Erik Penser Healthcare day

February 24, 2022

Oskar Bosson, VP Communications & Investor Relations, presented at the Erik Penser Healthcare day in Stockholm

Full Year Report 2021

February 3, 2022

A time of hope for Alzheimer’s patients

SEB Nordic Healthcare Seminar

January 18, 2022

Gunilla Osswald, CEO, presented BioArctic at the SEB Nordic Healthcare Seminar in Stockholm

New company presentation

November 15, 2021

BioArctic has updated its company presentation following the CTAD congress and recent news flow.

New data on lecanemab presented at the CTAD Alzheimer conference

November 15, 2021

BioArctic and partner Eisai held several oral presentations at the 14th Clinical Trials on Alzheimer’s Disease (CTAD) conference, November 9-12, 2021, revealing new data on lecanemab ...

The Swedish-American Life Science Summit 2021

October 22, 2021

Gunilla Osswald, CEO, presented BioArctic at the Swedish-American Life Science Summit (SALSS) in Stockholm

Interim report July – September 2021

October 21, 2021

Eisai initiates Biologics License Application of lecanemab in the US earlier than expected

Redeye Neurology Seminar CNS

October 13, 2021

Gunilla Osswald, CEO, presented BioArctic at the Redeye Neurology Seminar CNS in Stockholm.

International Congress of Parkinsons disease and movement disorders® (MDS)

September 20, 2021

BioArctics Head of Research, Johanna Fälting, presented at the International Congress of Parkinsons disease and movement disorders® (MDS).

Pareto Healthcare Conference

September 2, 2021

Gunilla Osswald, CEO, presented BioArctic at the Pareto Healthcare Conference in Stockholm.

Nordea Small and Mid Cap Days

August 26, 2021

Gunilla Osswald, CEO, presented BioArctic at the Nordea Small and Mid Cap Days in Stockholm.

Eisai presented latest data from the lecanemab clinical program at AAIC 2021

July 30, 2021

BioArctic AB’s partner Eisai held several presentations at the Alzheimer’s Association International Conference (AAIC) in Denver, Colorado July 26 to 30, 2021. The presentations included the ...

Interim report April – June 2021

July 9, 2021

FDA grants Breakthrough Therapy designation for lecanemab

ABGSC Life Science Summit 2021

May 25, 2021

Gunilla Osswald, CEO, presented BioArctic at the ABGSC Life Science Summit in Stockholm.

Aktiedagen Stockholm

May 4, 2021

On May 4 at 9:30 CET, BioArctic’s VP Communications and Investor Relations, Oskar Bosson, presented BioArctic at a Capital Markets Day hosted by Aktiespararna. The presentation ...

Interim Report January – March 2021

April 21, 2021

New data continues to strengthen lecanemab

BioArctic and Eisai presented latest data regarding lecanemab at AD/PD 2021

March 15, 2021

BioArctic AB and its partner Eisai presented new data on the drug candidate lecanemab (BAN2401) at the 15th International Conference on Alzheimer’s and Parkinson’s Diseases and ...

Full Year Report January – December 2020 – Presentation

February 4, 2021

New data provides further support for BAN2401 (lecanemab)

Erik Penser Bank Bolagsdag

November 26, 2020

On November 25 at 10:05 CET, BioArctic's VP Communications and Investor Relations, Oskar Bosson, presented BioArctic at a Capital Markets Day hosted by Erik Penser Bank. ...

Avanza’s Capital Markets Day 2020

November 12, 2020

On November 18 at 08:00 CET, BioArctic's CEO, Gunilla Osswald, presented BioArctic at Avanza's Capital Markets Day 2020. The presentation was broadcasted live via this link ...

Eisai presented latest data regarding drug candidate BAN2401 at CTAD 2020

November 9, 2020

BioArctic's partner Eisai presented new data on the drug candidate BAN2401 (lecanemab) at the Clinical Trials on Alzheimer’s Disease conference (CTAD), November 4-7. The presentations included ...

Interim Report January – September 2020

October 14, 2020

An additional Phase 3 study in Alzheimer’s disease

Pareto Healthcare Conference

September 3, 2020

Gunilla Osswald, CEO, presented BioArctic at the Pareto Healthcare Conference in Stockholm.

Alzheimer’s Association International Conference® 2020 (AAIC®)

July 30, 2020

BioArctic’s partner Eisai presented the latest data from the open-label extension of the Phase 2b study with the investigational BAN2401 in early Alzheimer’s disease. The preliminary ...

Interim Report for the period January – June 2020

July 10, 2020

Continued performance according to plan

Redeye Growth Day – presentation and interview

June 2, 2020

Gunilla Osswald, CEO, presented BioArctic at the Redeye Growth Day in Stockholm. Redeye interviewed Gunilla Osswald, CEO, and talked about innovation, sustainability and how BioArctic can ...

ABGSC – Life Science Summit

May 26, 2020

Gunilla Osswald, CEO, presented BioArctic at the ABGSC Life Science Summit in Stockholm.

Interim Report January – March 2020 – Presentation

April 22, 2020

Operations performing according to plan

Stockholm Corporate Finance Life Science Seminar

March 11, 2020

Gunilla Osswald, CEO, presented BioArctic and answered questions at the Stockholm Corporate Finance Life Science Seminar in Stockholm, Sweden. Link to BioArctic presentation and question and ...

9th Annual SVB Leerink Global Healthcare Conference in New York

February 27, 2020

Gunilla Osswald, CEO, presented BioArctic at 9th Annual SVB Leerink Global Healthcare Conference in New York.

Full Year Report January – December 2019 – Presentation

February 6, 2020

Enhanced project portfolio from a successful year

DNB Nordic Healthcare conference

December 12, 2019

Gunilla Osswald, CEO, presented BioArctic at DNB Nordic Healthcare conference in Oslo.

Clinical Trials in Alzheimer’s Disease (CTAD) conference

December 5, 2019

Presentations related to BAN2401 were given at the Clinical Trials on Alzheimer’s Disease (CTAD) Conference, held December 4-7 in San Diego, USA. BioArctic’s partner Eisai presented ...

Nordea Innovation Seminar

November 26, 2019

Gunilla Osswald, CEO, presented BioArctic at Nordea Innovation Seminar in Stockholm.

Interim Report January – September 2019 – Presentation

October 24, 2019

BioArctic: Strong continued progress year to date

Redeye Neurology Seminar

October 3, 2019

Gunilla Osswald, CEO, presents BioArctic and participates in a panel discussion at the Redeye Neurology Seminar in Stockholm, Sweden. BioArctic presentation (in Swedish) Panel discussion (in ...

Alzheimer’s Association International Conference 2019 in Los Angeles

July 18, 2019

The antibody BAN2401 was designed and generated to selectively target toxic protofibrils and oligomers, soluble aggregated forms of amyloid-beta.

Interim Report January – June 2019 – Presentation

July 11, 2019

BioArctic: Significant progress in the projects and additional milestone payment

Redeye – CEO interview

June 25, 2019

Get to know BioArctic’s CEO Gunilla Osswald, an interview by Redeye’s Equity Analyst Eddie Palmgren. Video (in Swedish).

Redeye Growth Day Presentation and Interview with EFN

June 10, 2019

Gunilla Osswald, CEO, presented BioArctic at the Redeye Growth Day in Stockholm, Sweden. Video (in Swedish) EFN Interview (in Swedish) https://www.efn.se/bors-finans/biorctic-ser-framgangar-inom-samtliga-omraden/

Jefferies 2019 Global Healthcare Conference

June 4, 2019

Gunilla Osswald, CEO, presented BioArctic at Jefferies 2019 Global Healthcare Conference in New York.

Interim Report January – March 2019 – Presentation

May 9, 2019

BioArctic’s partner Eisai initiated Phase 3-study with BAN2401 in Alzheimer’s disease. Phase 1-study with ABBV-0805 in the Parkinson program started

BioStock Live panel discussion “The Alzheimer Challenge”

April 29, 2019

Watch the replay of the panel discussion on April 29th at BioStock on "The Alzheimer Challenge" with BioArctic's CEO, Gunilla Osswald.

Redeye – CEO presentation and interview

April 3, 2019

Gunilla Osswald, CEO, presented BioArctic at Redeye’s lunch meeting in Stockholm, Sweden, on April 3.

Carnegie Nordic Healthcare Seminar

March 5, 2019

Gunilla Osswald, CEO, presented BioArctic at the Carnegie Nordic Healthcare Seminar in Stockholm, Sweden.

Full Year Report January – December 2018 – Presentation

February 14, 2019

BioArctic’s partner Eisai will initiate BAN2401 confirmatory Phase 3-study in early Alzheimer’s disease. AbbVie in-licensed the Parkinson portfolio.

Redeye – CEO interview

February 4, 2019

BioArctic announced on February 4 that Eisai will initiate Phase 3 confirmatory study with BAN2401 in early Alzheimer’s Disease. Interview with CEO Gunilla Osswald here.

Aktiespararna Life Science in Stockholm

January 21, 2019

Gunilla Osswald, CEO, presented BioArctic at Aktiespararna’s Life Science evening event in Stockholm, Sweden, on January 21.

Interview with Gunilla Osswald, CEO

December 14, 2018

Gunilla Osswald, CEO, was interviewed by Klas Palin, life science analyst at Redeye, in Stockholm on December 14, 2018.

DNB’s Annual Nordic Healthcare Conference in Oslo

December 12, 2018

Gunilla Osswald, CEO, presented BioArctic at DNB’s 9th Nordic Healthcare Conference in Oslo, Norway, on December 12.

Nordea Tech & Medtech/Life Science Seminar in Stockholm

November 27, 2018

Gunilla Osswald, CEO, presented BioArctic at the Nordea Tech & Medtech/Life Science Seminar in Stockholm, Sweden, on November 27.

Stora Aktiedagen in Stockholm

November 26, 2018

Gunilla Osswald, CEO, presented BioArctic at the “Stora Aktiedagen” in Stockholm, Sweden, on November 26.

Jefferies 2018 London Healthcare Conference

November 15, 2018

Gunilla Osswald, CEO, presented BioArctic at Jefferies 2018 London Healthcare Conference.

Biotech and Money in London

November 13, 2018

Gunilla Osswald, CEO, presented BioArctic at Biotech and Money, Investival Showcase, on November 13 in London.

Interim Report January – September 2018 – Presentation

November 8, 2018

BioArctic reports strong BAN2401 Phase 2b results for Alzheimer patients. AbbVie exercises its option to a license for Parkinson’s projects.

Redeye CNS Biotech Seminar

October 4, 2018

Gunilla Osswald, PhD, CEO, presents BioArctic at Redeye CNS Biotech Seminar in Stockholm, Sweden.

Interim Report January – June 2018 – Presentation

August 23, 2018

Positive results of the BAN2401 Phase 2b study in early Alzheimer’s disease

Redeye Growth Day

June 4, 2018

Gunilla Osswald, PhD, CEO, presents BioArctic at Redeye Growth Day in Stockholm, Sweden.

Annual General Meeting 2018

May 15, 2018

Presentation at BioArctic AB's Annual General Meeting 2018.

Interim Report January – March 2018 – Presentation

April 26, 2018

Continued progress of the project portfolio.

Carnegie Healthcare Seminar 2018

March 14, 2018

Gunilla Osswald, PhD, CEO, presented BioArctic at the Carnegie Healthcare Seminar 2018 on March 14 in Stockholm, Sweden.

11th Annual European Life Sciences CEO Forum & Exhibition for Partnering & Investing in Biotech & Pharma Industry, Zurich, Switzerland

February 26, 2018

Gunilla Osswald, CEO of BioArctic AB, presented the company at the 11th Annual European Life Sciences CEO Forum & Exhibition for Partnering & Investing in Biotech ...